Clinical Trials Browser

Terminated × Has results × Hereditary Sensory and Autonomic Neuropathies × Clear all

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04899349 2024-10-09

EPIK-B4

Phase 2 Terminated

2 enrolled 8 charts

Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Phase 2 Terminated

74 enrolled 40 charts

Myeloid

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

NCT02204982 2023-09-28

DYNAMO + R

Phase 3 Terminated

13 enrolled 10 charts 1 FDA

Lymphoid

Lymphoma, Follicular, Hereditary Sensory and Autonomic Neuropathies

NCT03565991 2023-09-25

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Phase 2 Terminated

202 enrolled 31 charts

Hereditary Sensory and Autonomic Neuropathies

NCT01942993 2020-09-30

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Phase 2 Terminated

3 enrolled 2 charts

Dermatologic

Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT01633060 2019-01-30

BELLE-3

Phase 3 Terminated

432 enrolled 20 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT02644122 2018-07-11

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Phase 2 Terminated

1 enrolled 6 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

Clinical Trials

Adjuvant Aspirin Treatment for Colon Cancer Patients

EPIK-B4

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

DYNAMO + R

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

BELLE-3

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes